Hamburg, Germany and Westminster, Colorado, USA, March 28, 2019 — Indivumed and Flagship Biosciences, Inc. are pleased to announce a partnership to expand their broad tissue-based biomarker development capabilities, as well as their clinical services to support advanced oncology diagnostics.
Under the terms of the agreement, the companies will offer a comprehensive set of services combining Flagship’s extensive experience in biomarker development, and Indivumed’s multiplex immunohistochemistry (IHC) assay development capabilities. In addition, Indivumed’s client base will benefit from Flagship’s artificial intelligence-enabled computational tissue analysis (cTA®) digital pathology platform which provides complimentary and comprehensive tissue profiling.
The complexity of tumor/immune interactions is creating a growing need to leverage advanced IHC services. Flagship’s platform will allow Indivumed’s clients to derive more accurate and informative data from their tissue samples. This joint effort will also expand Indivumed’s portfolio of services by providing full College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified testing capabilities.
Both Indivumed and Flagship share a goal to help accelerate the development and deployment of new treatment and diagnostic tools and will keep exploring options to expand cooperation toward this goal.
“This is an exciting development for us”, said Dr. Hartmut Juhl, CEO of Indivumed. “Flagship has a high reputation as a supplier of advanced IHC services and their CAP-CLIA environment is a perfect complement to our own testing facilities in Hamburg. Furthermore, both companies are engaged in Artificial Intelligence and Machine Learning projects opening multiple opportunities for future collaboration.”
“We are honored to be teaming with Indivumed to expand services in the clinical space. Indivumed is an ideal partner given their deep experience and leadership in the global oncology field. We are committed to advancing development in immune-oncology with the combined set of capabilities represented by this partnership,” said Trevor D. Johnson, Flagship Biosciences CEO.
INDIVUMED a global oncology research company based in Hamburg, Germany, has established the world’s leading multi-omics cancer database and biobank. Its proprietary processes and technology preserve the patterns of biomolecules such as RNA, DNA, and proteins as they existed in the human body. The cancer database contains genomics, transcriptomics, proteomics, phospho-proteomics and immuno-phenotype imaging information together with clinical and outcome data, making it a unique resource for cancer research in the post-genomics era. With leading edge data analytics capabilities, the cancer library allows for in-depth understanding of the underlying mechanisms of a patient’s cancer, addressing important demands in translational research and molecular diagnostics to support implementation of personalized healthcare. www.indivumed.com
About Flagship Biosciences
Flagship Biosciences, Inc. is an advanced tissue analysis services company delivering science-based innovation for improved drug development. The company offers a full range of tissue analysis services, using its award-winning technology, to deliver breakthrough contextual data supported by a team of experienced pathologists and scientists. It caters to pharmaceutical, biotechnology, and medical device companies. Flagship Biosciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado. www.flagshipbio.com
For more information or to schedule interviews with the companies’ principals please contact for Indivumed, Fernando Andreu, Chief Business Officer, at firstname.lastname@example.org or +1 (301) 785 1670, and for Flagship, Pamela Curran, Stratos Global Marketing, at email@example.com or +1 (303) 818 9316.